On the other hand, the basis for antigen presentation and anti-tumor effector mechanisms are less obvious in the context of MHC IINEG tumors (25, 26, 31, 70) – simply because such cancer cells cannot directly stimulate MHC class II-restricted CD4+ T cells (Figure 1). This evidence concerns the gene CD4 and neoplasm.